Annual EBIT
-$133.89 M
+$142.50 M+51.56%
31 December 2023
Summary:
Inovio Pharmaceuticals annual earnings before interest & taxes is currently -$133.89 million, with the most recent change of +$142.50 million (+51.56%) on 31 December 2023. During the last 3 years, it has risen by +$20.29 million (+13.16%). INO annual EBIT is now -2429.94% below its all-time high of -$4.67 million.INO EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$25.17 M
+$7.07 M+21.94%
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly earnings before interest & taxes is currently -$25.17 million, with the most recent change of +$7.07 million (+21.94%) on 30 September 2024. Over the past year, it has increased by +$8.45 million (+25.14%). INO quarterly EBIT is now -209.82% below its all-time high of $22.92 million, reached on 30 September 2020.INO Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$112.42 M
+$8.45 M+6.99%
30 September 2024
Summary:
Inovio Pharmaceuticals TTM earnings before interest & taxes is currently -$112.42 million, with the most recent change of +$8.45 million (+6.99%) on 30 September 2024. Over the past year, it has increased by +$50.91 million (+31.17%). INO TTM EBIT is now -6220.12% below its all-time high of -$1.78 million, reached on 31 March 1999.INO TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +51.6% | +25.1% | +31.2% |
| 3 y3 years | +13.2% | +57.8% | +48.0% |
| 5 y5 years | -41.2% | -19.2% | -2.0% |
INO EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +55.6% | -1.8% | +76.7% | at high | +68.0% |
| 5 y | 5 years | -41.2% | +55.6% | -209.8% | +79.9% | -2.0% | +68.0% |
| alltime | all time | -2429.9% | +55.6% | -209.8% | +79.9% | -6220.1% | +68.0% |
Inovio Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$25.17 M(-21.9%) | -$112.42 M(-7.0%) |
| June 2024 | - | -$32.24 M(+6.4%) | -$120.87 M(-2.4%) |
| Mar 2024 | - | -$30.29 M(+22.5%) | -$123.85 M(-7.5%) |
| Dec 2023 | -$133.89 M(-51.6%) | -$24.72 M(-26.5%) | -$133.89 M(-18.0%) |
| Sept 2023 | - | -$33.62 M(-4.6%) | -$163.32 M(-2.3%) |
| June 2023 | - | -$35.22 M(-12.7%) | -$167.18 M(-30.4%) |
| Mar 2023 | - | -$40.34 M(-25.5%) | -$240.14 M(-13.1%) |
| Dec 2022 | -$276.40 M(-8.3%) | -$54.15 M(+44.5%) | -$276.40 M(-15.9%) |
| Sept 2022 | - | -$37.47 M(-65.4%) | -$328.72 M(-6.3%) |
| June 2022 | - | -$108.18 M(+41.2%) | -$350.94 M(+8.2%) |
| Mar 2022 | - | -$76.59 M(-28.1%) | -$324.43 M(+7.7%) |
| Dec 2021 | -$301.29 M(+95.4%) | -$106.47 M(+78.4%) | -$301.29 M(+39.4%) |
| Sept 2021 | - | -$59.69 M(-26.9%) | -$216.17 M(+61.9%) |
| June 2021 | - | -$81.67 M(+52.8%) | -$133.56 M(-24.7%) |
| Mar 2021 | - | -$53.45 M(+150.4%) | -$177.31 M(+15.0%) |
| Dec 2020 | -$154.19 M(+36.6%) | -$21.35 M(-193.2%) | -$154.19 M(-8.4%) |
| Sept 2020 | - | $22.92 M(-118.3%) | -$168.41 M(-20.7%) |
| June 2020 | - | -$125.42 M(+313.5%) | -$212.43 M(+85.5%) |
| Mar 2020 | - | -$30.33 M(-14.7%) | -$114.50 M(+1.4%) |
| Dec 2019 | -$112.86 M(+19.1%) | -$35.57 M(+68.5%) | -$112.86 M(+2.4%) |
| Sept 2019 | - | -$21.11 M(-23.2%) | -$110.26 M(-3.4%) |
| June 2019 | - | -$27.49 M(-4.2%) | -$114.16 M(+22.3%) |
| Mar 2019 | - | -$28.70 M(-12.9%) | -$93.31 M(-4.2%) |
| Dec 2018 | -$94.80 M(+7.5%) | -$32.96 M(+31.8%) | -$97.36 M(+6.0%) |
| Sept 2018 | - | -$25.02 M(+276.8%) | -$91.83 M(-4.3%) |
| June 2018 | - | -$6.64 M(-79.7%) | -$96.00 M(-3.0%) |
| Mar 2018 | - | -$32.75 M(+19.4%) | -$98.99 M(+12.3%) |
| Dec 2017 | -$88.18 M(+14.2%) | -$27.42 M(-6.0%) | -$88.18 M(+6.1%) |
| Sept 2017 | - | -$29.19 M(+202.9%) | -$83.12 M(+12.1%) |
| June 2017 | - | -$9.64 M(-56.1%) | -$74.13 M(-11.5%) |
| Mar 2017 | - | -$21.93 M(-1.9%) | -$83.72 M(+8.4%) |
| Dec 2016 | -$77.24 M(+118.9%) | -$22.36 M(+10.7%) | -$77.24 M(+11.3%) |
| Sept 2016 | - | -$20.20 M(+5.0%) | -$69.40 M(+52.6%) |
| June 2016 | - | -$19.23 M(+24.4%) | -$45.47 M(+7.3%) |
| Mar 2016 | - | -$15.45 M(+6.4%) | -$42.37 M(+20.1%) |
| Dec 2015 | -$35.28 M(-10.7%) | -$14.53 M(-489.4%) | -$35.28 M(+11.1%) |
| Sept 2015 | - | $3.73 M(-123.1%) | -$31.77 M(-27.5%) |
| June 2015 | - | -$16.12 M(+92.6%) | -$43.83 M(+15.8%) |
| Mar 2015 | - | -$8.37 M(-24.0%) | -$37.86 M(-4.1%) |
| Dec 2014 | -$39.50 M(+83.3%) | -$11.01 M(+32.2%) | -$39.50 M(+5.4%) |
| Sept 2014 | - | -$8.33 M(-17.9%) | -$37.49 M(+32.0%) |
| June 2014 | - | -$10.15 M(+1.5%) | -$28.39 M(+14.0%) |
| Mar 2014 | - | -$10.00 M(+11.1%) | -$24.91 M(+15.6%) |
| Dec 2013 | -$21.54 M(-12.6%) | -$9.00 M(-1276.1%) | -$21.54 M(+14.8%) |
| Sept 2013 | - | $765.60 K(-111.5%) | -$18.77 M(-28.7%) |
| June 2013 | - | -$6.67 M(+0.6%) | -$26.33 M(-0.4%) |
| Mar 2013 | - | -$6.63 M(+6.5%) | -$26.44 M(+7.3%) |
| Dec 2012 | -$24.64 M(+10.9%) | -$6.23 M(-8.3%) | -$24.64 M(+1.8%) |
| Sept 2012 | - | -$6.79 M(+0.1%) | -$24.20 M(+0.5%) |
| June 2012 | - | -$6.79 M(+40.3%) | -$24.08 M(+7.4%) |
| Mar 2012 | - | -$4.84 M(-16.3%) | -$22.43 M(+0.9%) |
| Dec 2011 | -$22.23 M | -$5.78 M(-13.4%) | -$22.23 M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$6.67 M(+29.9%) | -$21.73 M(+10.8%) |
| June 2011 | - | -$5.14 M(+10.8%) | -$19.61 M(+0.8%) |
| Mar 2011 | - | -$4.64 M(-12.2%) | -$19.45 M(+1.2%) |
| Dec 2010 | -$19.22 M(+37.7%) | -$5.28 M(+15.9%) | -$19.22 M(+8.3%) |
| Sept 2010 | - | -$4.56 M(-8.4%) | -$17.75 M(+5.7%) |
| June 2010 | - | -$4.98 M(+12.9%) | -$16.79 M(+13.4%) |
| Mar 2010 | - | -$4.41 M(+15.7%) | -$14.80 M(+6.1%) |
| Dec 2009 | -$13.96 M(+2.2%) | -$3.81 M(+6.0%) | -$13.96 M(+2.6%) |
| Sept 2009 | - | -$3.60 M(+20.3%) | -$13.61 M(+6.6%) |
| June 2009 | - | -$2.99 M(-16.0%) | -$12.76 M(-8.0%) |
| Mar 2009 | - | -$3.56 M(+2.9%) | -$13.87 M(+1.6%) |
| Dec 2008 | -$13.66 M(-14.1%) | -$3.46 M(+25.9%) | -$13.66 M(+13.7%) |
| Sept 2008 | - | -$2.75 M(-33.0%) | -$12.01 M(-15.9%) |
| June 2008 | - | -$4.10 M(+22.6%) | -$14.29 M(-4.4%) |
| Mar 2008 | - | -$3.35 M(+84.7%) | -$14.94 M(-6.0%) |
| Dec 2007 | -$15.90 M(+19.1%) | -$1.81 M(-64.0%) | -$15.90 M(-11.1%) |
| Sept 2007 | - | -$5.03 M(+5.7%) | -$17.88 M(+9.1%) |
| June 2007 | - | -$4.76 M(+10.5%) | -$16.39 M(+10.5%) |
| Mar 2007 | - | -$4.30 M(+13.4%) | -$14.84 M(+11.2%) |
| Dec 2006 | -$13.35 M(+9.6%) | -$3.79 M(+7.3%) | -$13.35 M(+5.8%) |
| Sept 2006 | - | -$3.54 M(+10.4%) | -$12.62 M(+4.2%) |
| June 2006 | - | -$3.20 M(+13.9%) | -$12.12 M(+9.2%) |
| Mar 2006 | - | -$2.81 M(-8.3%) | -$11.10 M(-8.8%) |
| Dec 2005 | -$12.18 M(+5.8%) | -$3.07 M(+1.1%) | -$12.17 M(-6.3%) |
| Sept 2005 | - | -$3.03 M(+38.8%) | -$12.99 M(-3.8%) |
| June 2005 | - | -$2.19 M(-43.8%) | -$13.50 M(-2.0%) |
| Mar 2005 | - | -$3.89 M(+0.0%) | -$13.78 M(+19.7%) |
| Dec 2004 | -$11.51 M(+73.5%) | -$3.89 M(+9.7%) | -$11.51 M(+22.0%) |
| Sept 2004 | - | -$3.54 M(+43.7%) | -$9.43 M(+24.3%) |
| June 2004 | - | -$2.47 M(+52.5%) | -$7.59 M(+16.3%) |
| Mar 2004 | - | -$1.62 M(-10.6%) | -$6.52 M(-1.9%) |
| Dec 2003 | -$6.63 M(+12.4%) | -$1.81 M(+6.5%) | -$6.65 M(+6.4%) |
| Sept 2003 | - | -$1.70 M(+21.3%) | -$6.25 M(+3.7%) |
| June 2003 | - | -$1.40 M(-19.8%) | -$6.03 M(-2.0%) |
| Mar 2003 | - | -$1.75 M(+23.8%) | -$6.15 M(+4.3%) |
| Dec 2002 | -$5.90 M(+1.1%) | -$1.41 M(-4.2%) | -$5.90 M(+31.4%) |
| Sept 2002 | - | -$1.47 M(-3.3%) | -$4.49 M(-5.0%) |
| June 2002 | - | -$1.52 M(+2.0%) | -$4.72 M(-20.5%) |
| Mar 2002 | - | -$1.49 M(-12.6%) | -$5.94 M(+5.8%) |
| Dec 2001 | -$5.84 M(+10.4%) | - | - |
| Sept 2001 | - | -$1.71 M(-37.6%) | -$5.61 M(-5.6%) |
| June 2001 | - | -$2.74 M(-348.9%) | -$5.95 M(+12.4%) |
| Mar 2001 | - | $1.10 M(-148.5%) | -$5.29 M(-40.7%) |
| Mar 2001 | -$5.29 M(-44.5%) | - | - |
| Dec 2000 | - | -$2.27 M(+11.0%) | -$8.93 M(+4.3%) |
| Sept 2000 | - | -$2.04 M(-1.8%) | -$8.56 M(+0.5%) |
| June 2000 | - | -$2.08 M(-17.9%) | -$8.52 M(-9.7%) |
| Mar 2000 | -$9.53 M(+38.6%) | -$2.53 M(+33.4%) | -$9.43 M(+72.2%) |
| Dec 1999 | - | -$1.90 M(-5.0%) | -$5.48 M(-19.2%) |
| Sept 1999 | - | -$2.00 M(-33.3%) | -$6.78 M(+41.9%) |
| June 1999 | - | -$3.00 M(-311.1%) | -$4.78 M(+168.7%) |
| Mar 1999 | -$6.88 M | $1.42 M(-144.4%) | -$1.78 M(-44.4%) |
| Dec 1998 | - | -$3.20 M | -$3.20 M |
FAQ
- What is Inovio Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual EBIT year-on-year change?
- What is Inovio Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals quarterly EBIT year-on-year change?
- What is Inovio Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals TTM EBIT year-on-year change?
What is Inovio Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of INO is -$133.89 M
What is the all time high annual EBIT for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual earnings before interest & taxes is -$4.67 M
What is Inovio Pharmaceuticals annual EBIT year-on-year change?
Over the past year, INO annual earnings before interest & taxes has changed by +$142.50 M (+51.56%)
What is Inovio Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of INO is -$25.17 M
What is the all time high quarterly EBIT for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly earnings before interest & taxes is $22.92 M
What is Inovio Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, INO quarterly earnings before interest & taxes has changed by +$8.45 M (+25.14%)
What is Inovio Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of INO is -$112.42 M
What is the all time high TTM EBIT for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high TTM earnings before interest & taxes is -$1.78 M
What is Inovio Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, INO TTM earnings before interest & taxes has changed by +$50.91 M (+31.17%)